July 26th 2024
The molecule can be a potential treatment that counters effects of early-life antibiotics, which can impact the gut microbiota and increase the risk of childhood atopy and asthma.
Toxic Stress Affects Children's Long-Term Health; Support Programs May Help
August 6th 2014Children who grow up in stressful settings are at higher risk of developmental problems that may later manifest as chronic disease. Fortunately, support programs may help reduce stress and improve outcomes.
Read More
FDA Expands Access to Lumizyme, Drops Risk Mitigation Requirements
August 5th 2014With its expanded approval of Lumizyme (alglucosidase alfa) to treat all Pompe disease patients, regardless of age or time of disease onset, the FDA has eliminated the Risk Evaluation and Mitigation Strategy program that restricted the drug's use to those aged 8 years or older with late-onset disease.
Read More